For instance, aberrant and compressed blood vasculature limits access of therapeutics to the tumor to begin with as well as tumor cells themselves have resistances that we have yet to define or target. To overcome this limitation and treat residual tumor cells, radiation and/or chemotherapeutics are usually a follow-up treatment which comes with its own shortcomings. Course of treatment for GBM normally includes initial resection of the tumor however, diffuse invasion of cells throughout the brain create a termed “moving target” for therapeutic access due to ineffective complete resection of tumor cells left behind. Due to the complex and sensitive architecture of the brain, efficacy and cytotoxicity are major concerns for developing ameliorative therapeutics that can cross the blood brain barrier and avoid damage to the intricate structures that are important for nervous system function.
Glioblastoma (GBM), the most aggressive form of brain cancer, presents with unique challenges compared to other forms of disease in regards to treatment.
0 kommentar(er)
